Literature DB >> 32236875

Hypophosphataemic Rickets: Similar Phenotype of Different Diseases.

Francisco de la Cerda-Ojeda1, Juan D González-Rodríguez2, Leire Madariaga3, Guillermo Martínez-Díaz-Guerra4, María L Matoses-Ruipérez5.   

Abstract

Hypophosphataemic rickets (HR) is a group of rare disorders caused by excessive renal phosphate wasting in which the participation of fibroblast growth factor 23 (FGF23) can be prominent. These diseases pose therapeutic challenges with important consequences for growth and bone development in childhood, with higher risk of fractures and poorer bone healing, dental problems, and nephrolithiasis or nephrocalcinosis. In some cases, the diagnostic delay can be very long; laboratory findings and an exhaustive anamnesis could help distinguish between various pathologies, and FGF23 values-although currently not routinely measured-have implications for the differential diagnosis. Genetic testing is encouraged, especially in sporadic or insidious cases. In this review we discuss the clinical features of HR, with a particular emphasis on the differential diagnosis and the therapeutic implications.

Entities:  

Keywords:  Cutaneous skeletal hypophosphataemia syndrome; Differential diagnosis; Hypophosphataemic rickets; McCune–Albright syndrome; Oncogenic osteomalacia; Orthopaedics

Mesh:

Substances:

Year:  2020        PMID: 32236875     DOI: 10.1007/s12325-019-01182-3

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  2 in total

1.  Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial.

Authors:  Noriyuki Namba; Takuo Kubota; Koji Muroya; Hiroyuki Tanaka; Masanori Kanematsu; Masahiro Kojima; Shunichiro Orihara; Hironori Kanda; Yoshiki Seino; Keiichi Ozono
Journal:  J Endocr Soc       Date:  2022-02-11

2.  Genetic analysis combined with 3D-printing assistant surgery in diagnosis and treatment for an X-linked hypophosphatemia patient.

Authors:  Jie-Yuan Jin; Li-Yang Zhang; Shuai Guo; Ke Tang; Lei Zeng; Rong Xiang; Jie-Yu Liang
Journal:  J Clin Lab Anal       Date:  2022-02-02       Impact factor: 2.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.